Pomerantz LLP is looking into claims on behalf of Flowserve Corporation (also known as “Eiger” or “the Company”) investors (NASDAQ: EIGR). Robert S. Willoughby can be reached at newaction@pomlaw.com or 888-476-6529, ext. 7980, if such investors wish to do so.

Whether Eiger and a few of its officials and/or directors have engaged in securities fraud or other illegal business practises is the subject of the investigation.
According to its most recent communications with the U.S. Food and Drug Administration (FDA), Eiger released a press release on September 6, 2022, “provid[ing] an update on the status of its planned request for emergency use authorization (EUA) of peginterferon lambda for the treatment of patients with mild-to-moderate COVID-19.” The company stated specifically that “[f]ollowing a cooperative and extensive pre-EUA information exchange with FDA regarding the Phase 3 TOGETHER study of peginterferon lambda for COVID-19, the agency has indicated that it is not yet able to determine whether the criteria for the submission of an application and issuance of an EUA are likely to be met.”

Source: Prnewswire